title: Glycoprotein IIb/IIIa inhibitors.
abstract: The role of glycoprotein (GP) IIb/IIIa inhibitors in interventional cardiology continues to evolve. This review focuses on contemporary research to evaluate the appropriate context for the use of GP IIb/IIIa inhibitors.
authors.affiliation: Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Desk F25, 9500 Euclid Avenue, Cleveland, OH 44195, USA. lincofa@ccf.org
authors.forename: A Michael
authors.initials: AM
authors.lastname: Lincoff
mesh_terms: D000077284:Abciximab; D054058:Acute Coronary Syndrome / Q000188:drug therapy; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000628:therapy*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage; D009204:Myocardial Revascularization; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab